Early this week, I joined Chris Spivey on PharmaTech.com’s Behind the Headlines to discuss several of the previous week’s significant life science events, including Eli Lilly’s acquisition of SiteOne Therapeutics (Link) and GSK’s acquisition of Efismetxxx from Boston Therapeutics (which I wrote about here).
Overall, it’s good to see activity returning in the BD space with these and then several large transactions this week: BMS signing a deal with BioNTech to work on a bispecific BNT327 with payments up to $ 11.1 billion (Link) and Sanofi buying Blueprint Medicines for ~ $9.5 billion (Link)
As we discussed in the call, the best thing for pharmaceutical companies to do right now, whether acquiring or developing in-house, is to look for products that solve a legitimate unmet need and that the pathway to market and commercial opportunity is well understood, regardless of the macro factors impacting our space.
Click here to listen to the episode: https://www.pharmtech.com/view/behind-the-headlines-episode-18-sanofi-gsk-go-big-in-m-a-mrna-momentum-falters-and-more